The alternative complement pathway revisited

Abstract

Introduction Methods to study and modify the alternative pathway Influence of AP amplification on the effect of specific activation of the other initial pathways Properdin Influence of AP in deficiency states Complement in sepsis Concluding remarks Alternative pathway amplification plays a major role for the final effect of initial specific activation of the classical and lectin complement pathways, but the quantitative role of the amplification is insufficiently investigated. In experimental models of human diseases in which a direct activation of alternative pathway has been assumed, this interpretation needs revision placing a greater role on alternative amplification. We recently documented that the alternative amplification contributed to 80–90% of C5 activation when the initial activation was highly specific for the classical pathway. The recent identification of properdin as a recognition factor directly initiating alternative pathway activation, like C1q in the classical and mannose‐binding lectin in the lectin pathway, initiates a renewed interest in the reaction mechanisms of complement. Complement and Toll‐like receptors, including the CD14 molecule, are two main upstream recognition systems of innate immunity, contributing to the inflammatory reaction in a number of conditions including ischaemia‐reperfusion injury and sepsis. These systems act as ‘double‐edged swords’, being protective against microbial invasion, but harmful to the host when activated improperly or uncontrolled. Combined inhibition of complement and Toll‐like receptors/CD14 should be explored as a treatment regimen to reduce the overwhelming damaging inflammatory response during sepsis. The alternative pathway should be particularly considered in this regard, due to its uncontrolled amplification in sepsis. The alternative pathway should be regarded as a dual system, namely a recognition pathway principally similar to the classical and lectin pathways, and an amplification mechanism, well known, but quantitatively probably more important than generally recognized.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 114

1. 1.

   Walport MJ. Complement. First of two parts. N Engl J Med. 2001;344:1058-66.

   Not in our library10.1056/nejm200104053441406

2. 2.

   Mollnes TE, Song WC, Lambris JD. Complement in inflammatory tissue damage and disease. Trends Immunol. 2002;23:61-4.

   Not in our library10.1016/s1471-4906(01)02129-9

3. 3.

   Volanakis JE, Kaplan MH. Interaction of C-reactive protein complexes with the complement system. II. Consumption of guinea pig complement by CRP complexes: requirement for human C1q. J Immunol. 1974;113:9-17.

   Not in our library

4. 4.

   Biro A, Rovo Z, Papp D, Cervenak L, Varga L, Fust G, Thielens NM, Arlaud GJ, Prohaszka Z. Studies on the interactions between C-reactive protein and complement proteins. Immunology. 2007;121:40-50.

   Not in our library10.1111/j.1365-2567.2007.02535.x

5. 5.

   Kang YS, Do Y, Lee HK, Park SH, Cheong C, Lynch RM, Loeffler JM, Steinman RM, Park CG. A dominant complement fixation pathway for pneumococcal polysaccha-rides initiated by SIGN-R1 interacting with C1q. Cell. 2006;125:47-58.

   Not in our library10.1016/j.cell.2006.01.046

6. 6.

   Paidassi H, Tacnet-Delorme P, Garlatti V, Darnault C, Ghebrehiwet B, Gaboriaud C, Arlaud GJ, Frachet P. C1q binds phos-phatidylserine and likely acts as a multili-gand-bridging molecule in apoptotic cell recognition. J Immunol. 2008;180:2329-38.

   Not in our library10.4049/jimmunol.180.4.2329

7. 7.

   Matsushita M, Fujita T. Ficolins and the lectin complement pathway. Immunol Rev. 2001;180:78-85.

   Not in our library10.1034/j.1600-065x.2001.1800107.x

8. 8.

   Roos A, Bouwman LH, Munoz J, Zuiverloon T, Faber-Krol MC, Fallaux-van den Houten FC, Klar-Mohamad N, Hack CE, Tilanus MG, Daha MR. Functional characterization of the lectin pathway of complement in human serum. Mol Immunol. 2003;39:655-68.

   Not in our library10.1016/s0161-5890(02)00254-7

9. 9.

   Garred P, Larsen F, Seyfarth J, Fujita R, Madsen HO. Mannose-binding lectin and its genetic variants. Genes Immun. 2006;7:85-94.

   Not in our library10.1038/sj.gene.6364283

10. 10.

    Thiel S. Complement activating soluble pattern recognition molecules with collagen-like regions, mannan-binding lectin, ficolins and associated proteins. Mol Immunol. 2007;44:3875-88.

    Not in our library10.1016/j.molimm.2007.06.005

11. 11.

    Krarup A, Thiel S, Hansen A, Fujita T, Jensenius JC. L-ficolin is a pattern recognition molecule specific for acetyl groups. J Biol Chem. 2004;279:47513-9.

    Not in our library10.1074/jbc.m407161200

12. 12.

    Tack BF, Harrison RA, Janatova J, Thomas ML, Prahl JW. Evidence for presence of an internal thiolester bond in third component of human complement. Proc Natl Acad Sci USA. 1980;77:5764-8.

    Not in our library10.1073/pnas.77.10.5764

13. 13.

    Pangburn MK, Muller-Eberhard HJ. Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med. 1980;152:1102-14.

    Not in our library10.1084/jem.152.4.1102

14. 14.

    Bexborn F, Andersson PO, Chen H, Nilsson B, Ekdahl KN. The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H(2)O)Bb). Mol Immunol. 2008;45:2370-9.

    Not in our library10.1016/j.molimm.2007.11.003

15. 15.

    Harboe M, Garred P, Borgen MS, Stahl GL, Roos A, Mollnes TE. Design of a complement mannose-binding lectin pathway-specific activation system applicable at low serum dilutions. Clin Exp Immunol. 2006;144:512-20.

    Not in our library10.1111/j.1365-2249.2006.03072.x

16. 16.

    Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR, Lambris JD, Warner RL, Flierl MA, Hoesel LM, Gebhard F, Younger JG, Drouin SM, Wetsel RA, Ward PA. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med. 2006;12:682-7.

    Not in our library10.1038/nm1419

17. 17.

    Walport MJ. Complement. Second of two parts. N Engl J Med. 2001;344:1140-4.

    Not in our library10.1056/nejm200104123441506

18. 18.

    Hill JH, Ward PA. The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med. 1971;133:885-900.

    Not in our library10.1084/jem.133.4.885

19. 19.

    Weisman HF, Bartow T, Leppo MK, Marsh HC, Carson GR, Concino MF, Boyle MP, Roux KH, Weisfeldt ML, Fearon DT. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science. 1990;249:146-51.

    Not in our library10.1126/science.2371562

20. 20.

    Chan RK, Ibrahim SI, Verna N, Carroll M, Moore FD, Hechtman HB. Ischaemia-reperfusion is an event triggered by immune complexes and complement. Br J Surg. 2003;90:1470-8.

    Not in our library10.1002/bjs.4408

21. 21.

    Zhang M, Austen WG, Chiu I, Alicot EM, Hung R, Ma M, Verna N, Xu M, Hechtman HB, Moore FD, Carroll MC. Identification of a specific self-reactive IgM antibody that initiates intestinal ischemia/reperfusion injury. Proc Natl Acad Sci USA. 2004;101:3886-91.

    Not in our library10.1073/pnas.0400347101

22. 22.

    Weiser MR, Williams JP, Moore FD, Kobzik L, Ma M, Hechtman HB, Carroll MC. Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J Exp Med. 1996;183:2343-8.

    Not in our library10.1084/jem.183.5.2343

23. 23.

    Williams JP, Pechet TT, Weiser MR, Reid R, Kobzik L, Moore FD, Carroll MC, Hechtman HB. Intestinal reperfusion injury is mediated by IgM and complement. J Appl Physiol. 1999;86:938-42.

    Not in our library10.1152/jappl.1999.86.3.938

24. 24.

    Stahl GL, Xu Y, Hao L, Miller M, Buras JA, Fung M, Zhao H. Role for the alternative complement pathway in ischemia/ reperfusion injury. Am J Pathol. 2003;162:449-55.

    Not in our library10.1016/s0002-9440(10)63839-4

25. 25.

    Fung M, Loubser PG, Undar A, Mueller M, Sun C, Sun WN, Vaughn WK, Fraser CD. Inhibition of complement, neu-trophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuits. J Thorac Cardiovasc Surg. 2001;122:113-22.

    Not in our library10.1067/mtc.2001.114777

26. 26.

    Harboe M, Ulvund G, Vien L, Fung M, Mollnes TE. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin Exp Immunol. 2004;138:439-46.

    Not in our library10.1111/j.1365-2249.2004.02627.x

27. 27.

    Spitzer D, Mitchell LM, Atkinson JP, Hourcade DE. Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J Immunol. 2007;179:2600-8.

    Not in our library10.4049/jimmunol.179.4.2600

28. 28.

    Kimura Y, Miwa T, Zhou L, Song WC. Activator-specific requirement of prop-erdin in the initiation and amplification of the alternative pathway complement. Blood. 2008;111:732-40.

    Not in our library10.1182/blood-2007-05-089821

29. 29.

    Stover CM, Luckett JC, Echtenacher B, Dupont A, Figgitt SE, Brown J, Mannel DN, Schwaeble WJ. Properdin plays a protective role in polymicrobial septic peritonitis. J Immunol. 2008;180:3313-8.

    Not in our library10.4049/jimmunol.180.5.3313

30. 30.

    Volanakis JE, Narayana SV. Complement factor D, a novel serine protease. Protein Sci. 1996;5:553-64.

    Not in our library10.1002/pro.5560050401

31. 31.

    Thurman JM, Kraus DM, Girardi G, Hourcade D, Kang HJ, Royer PA, Mitchell LM, Giclas PC, Salmon J, Gilkeson G, Holers VM. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol Immunol. 2005;42:87-97.

    Not in our library10.1016/j.molimm.2004.07.043

32. 32.

    Gupta-Bansal R, Parent JB, Brunden KR. Inhibition of complement alternative pathway function with anti-properdin monoclonal antibodies. Mol Immunol. 2000;37:191-201.

    Not in our library10.1016/s0161-5890(00)00047-x

33. 33.

    Xu Y, Ma M, Ippolito GC, Schroeder HW, Carroll MC, Volanakis JE. Complement activation in factor D-deficient mice. Proc Natl Acad Sci USA. 2001;98:14577-82.

    Not in our library10.1073/pnas.261428398

34. 34.

    Matsumoto M, Fukuda W, Circolo A, Goellner J, Strauss-Schoenberger J, Wang X, Fujita S, Hidvegi T, Chaplin DD, Colten HR. Abrogation of the alternative complement pathway by targeted deletion of murine factor B. Proc Natl Acad Sci USA. 1997;94:8720-5.

    Not in our library10.1073/pnas.94.16.8720

35. 35.

    Truedsson L, Westberg J, Fredrikson GN, Sjoholm AG, Kuijper EJ, Fijen CA, Spath PJ, Uhlen M. Human properdin deficiency has a heterogeneous genetic background. Immunopharmacology. 1997;38:203-6.

    Not in our library10.1016/s0162-3109(97)00087-8

36. 36.

    Van Den Boogard R, Fijen CA, Schipper MG, de Galan L, Kuijper EJ, Mannens MM. Molecular characterisation of 10 Dutch properdin type I deficient families: mutation analysis and X-inactivation studies. Eur J Hum Genet. 2000;8:513-8.

    Not in our library10.1038/sj.ejhg.5200496

37. 37.

    Bathum L, Hansen H, Teisner B, Koch C, Garred P, Rasmussen K, Wang P. Association between combined properdin and mannose-binding lectin deficiency and infection with Neisseria meningitidis. Mol Immunol. 2006;43:473-9.

    Not in our library10.1016/j.molimm.2005.02.017

38. 38.

    Hart ML, Ceonzo KA, Shaffer LA, Takahashi K, Rother RP, Reenstra WR, Buras JA, Stahl GL. Gastrointestinal ischemia-reperfusion injury is lectin complement pathway dependent without involving C1q. J Immunol. 2005;174:6373-80.

    Not in our library10.4049/jimmunol.174.10.6373

39. 39.

    Walsh MC, Bourcier T, Takahashi K, Shi L, Busche MN, Rother RP, Solomon SD, Ezekowitz RA, Stahl GL. Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. J Immunol. 2005;175:541-6.

    Not in our library10.4049/jimmunol.175.1.541

40. 40.

    Austen WG, Zhang M, Chan R, Friend D, Hechtman HB, Carroll MC, Moore FD. Murine hindlimb reperfusion injury can be initiated by a self-reactive monoclonal IgM. Surgery. 2004;136:401-6.

    Not in our library10.1016/j.surg.2004.05.016

Cited by papers we hold 5

• Anaphylatoxins spark the flame in early autoimmunity · 2022
  Not checked
• Complement factor H contributes to mortality in humans and mice with bacterial meningitis · 2019
  Not checked
• A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation · 2019
  No notice
• The Alternative Complement System Mediates Cell Death in Retinal Ischemia Reperfusion Injury · 2018
  Not checked
• Complement System Part I – Molecular Mechanisms of Activation and Regulation · 2015
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.